Orrick advised SFJ on its acquisition of assets related to the drug Bentracimab from PhaseBio.

Orrick is advising Ipsen (Euronext: IPN: ADR: IPSEY) on its acquisition of Albireo Pharma Inc (NASDAQ: ALBO), a leading innovator in bile-acid ...

Orrick advised South San Francisco-based biopharmaceutical company Catalyst Biosciences, Inc. in its acquisition of the F351 program, a ...

Orrick advised clinical-stage biotech company BioAtla on the sale of 9,745,128 shares of its common stock in an underwritten offering.

Congratulations to our client Qualifacts on its acquisition of OnCall Health, a telehealth, patient portal and client engagement technology provider.

Orrick advised Bayer on its three-year strategic partnership with biotech company Ginkgo Bioworks to accelerate the research and development of ...

The investment marks the first time MY DR NOW has received external capital.

After a long and complex prenotification phase before the European Commission, Orrick obtained an early unconditional clearance of the transaction.

We advised Sosei Heptares, an international biopharmaceutical company and world-leader in G protein-coupled receptor (GPCR) focused structure-based ...

Medical Microinstruments is a robotics company dedicated to improving clinical outcomes for patients undergoing microsurgery.

Orrick advised German biopharmaceutical company MorphoSys on its equity participation transaction with biotech company Human Immunology Biosciences

Joseph Perkins and Stephen Thau explain how early-stage biotech startups can use DAOs to provide an alternative to traditional sources of capital.

Following our first article on IP due diligence considerations for prospective investors of emerging life sciences companies, we’re taking an ...

How the right level of IP due diligence can help inform investment decisions in the life sciences arena.

ESG factors are increasingly important in the life sciences. Managing ESG risks and opportunities can be an important source of long-term value.

German universities increasingly are becoming entrepreneurial hotbeds, though university spin-offs face unique challenges.

The last year has seen a multijurisdictional regulatory push for increased cybersecurity standards for medical devices. Here's what you need to know.

Leveraging Non-Dilutive Financing For Drug Development and Favorably Licensing Developed Products as a Global Health Model

Two of our partners and an Andersen director author Law360 article on tax implications in LSC collaboration deals.

Franklin Monsour posted this article on Law360 on taking more FCA cases to trial.

EU & US Privacy and Security Considerations for Covid-19 Data Processing Activities From Pandemic to Living with Covid written by Thora Johnson.

Our lawyers wrote Newsweek opinion piece calling for federal legislation to address privacy vulnerabilities after Dobbs.

Evolving Antitrust Scrutiny of Life Sciences M&A—What's in the Pipeline?

Partners from Orrick's Cyber, Privacy & Data Innovation Group partnered with the AHLA to explore the legal framework that helps to protect health ...

Welcome to David Gindler, Gary Frischling, Lauren Drake and John Yu, who join us as partners in Southern California.

Anna Aryankalayil will join the firm Nov. 14 as a partner in our Antitrust and Competition practice.

Congratulations to all of the members of the Orrick Life Sciences team recognized at this year’s LMG Life Sciences Awards.

American Lawyer has twice before recognized Josh as Litigator of Year.

In the first half of 2022, our teams advised on 80 mergers, acquisitions, VC financings and other transactions in the Life Sciences sector.

Congratulations to Orrick partner Gregg Griner on being recognized as a Go-To Lawyer for Healthcare and Life Sciences by Massachusetts Lawyers Weekly.

Welcome to Tony Chan who joins the firm as a partner focused on advising companies and investors in the life sciences and tech sectors.

Eileen Cole and Craig Falls join the firm as partners in our Antitrust and Competition practice.

Orrick welcomes Franklin Monsour, a former federal prosecutor and experienced white collar and regulatory adviser to the life sciences sector.

LMG recognizes the individuals and companies behind the most innovative and challenging life sciences work of the past year.